Clinical efficacy of a new HMG-CoA reductase inhibitor, BAY w 6228: A dose finding among four groups by the double blind method

Japanese Pharmacology and Therapeutics

Volumn 24, Issue SUPPL. 9, 1996, Pages 87-115

  Goto, Yuichiro ^a  

^a TOKAI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; PATIENT COMPLIANCE;

EID: 0029853387     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Multiple Risk Factor Intervention Trial Research Group : Multiple risk factor intervention trial. JAMA 248 : 1465-1477, 1982
2. Assmann G, Schulte H : The Prospective Cardiovascular Münster (PROCAM) study ; Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 116 : 1713-1724, 1988
3. Report from Committee of Principal Investigators : A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40 : 1069-1118, 1978
4. Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results (I ) ; Reduction in incidence of coronary heart disease. JAMA 251 : 351-364, 1984
5. Lipid Research Clinics Program : The lipid research clinics coronary primary prevention trial results (II) ; The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251 : 365-374, 1984
6. Frick MH et al : Helsinki heart study ; Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia ; Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Eng J Med 317 : 1237-1245, 1987
7. The Pravastatin Multinational Study Group for Cardiac Risk Patients : Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72 : 1031-1037, 1993
8. Scandinavian Simvastatin Survival Study Group : Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease ; The Scandinavian simvastatin survival study (4S). Lancet 344 : 1383-1389, 1994
9. Hilmar B et al : Pharmacology of the new highly potent HMG-CoA reductase inhibitor cerivastatin (BAY w 6228). Atherosclerosis (in press)
10. Friedewald WT et al : Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 : 499-502, 1972
11. Bradford RH et al : Expanded clinical evaluation of lovastatin (EXCEL) study results. Arch Int Med 151 : 43-49, 1991
12. Faggiotto A, Montagner FP : BAY w 6228-a new generation HMG-CoA reductase inhibitor. XI Int Symp Drugs Affecting Lipid Metabolism (Florence), 1992
13. Edwards PA : Turnover rate of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase as determined by use of cycloheximide. J Biol Chem 247 : 1520-1524, 1972
14. Allenby KS et al : A double-blind placebo-controlled dose scheduling study of BAY w 6228 in doses of 100 μg twice daily with breakfast and dinner compared to 200 μg once daily with dinner or at bedtime in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther (in press)
15. Benfante R, Reed D : Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly. JAMA 263 : 393-396, 1990
16. Carlson LA, Bottiger LE : Serum triglycerides, to be or not to be a risk factor for ischemic heart disease? Atherosclerosis 39 : 287-291, 1981
17. Castelli WP : The triglyceride issue ; A view from Framingham. Am Heart J 112 : 432-437, 1986
18. Bakker-Arkema R et al : Atorvastatin, a new HMG-CoA reductase inhibitor(HMGRI), is safe and effective in hypertriglyceridemic patients. Xth Int Symp Atherosclerosis, 1994